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AbstrACt
Objective to compare 2 years of radiographic sacroiliac 
joint (SIJ) changes in patients with recent onset axial 
spondyloarthritis (axSpA) receiving etanercept in a 
clinical trial (EMBArK) to similar patients not receiving 
biologics in a cohort study (dESIr).
Methods Endpoints were changes at week 104 per 
the modified new York (mnY) grading system in total SIJ 
score (primary endpoint) and net percentage of patients 
with progression defined three ways. treatment effect 
was analysed with and without adjustment for baseline 
covariates.
results At 104 weeks, total SIJ score improved in 
the etanercept group (n=154, adjusted least-squares 
mean change: –0.14) and worsened in the control 
group (n=182, change: 0.08). the adjusted difference 
between groups (etanercept minus control) was –0.22 
(95% CI –0.38 to –0.06), p=0.008. the net percentage 
of patients with progression was significantly lower 
in the etanercept versus the control group for two of 
three binary endpoints: –1.9% versus 1.6% (adjusted 
difference for etanercept minus control: –4.7%,95% CI 
–9.9 to 0.5, p=0.07) for change in mnY criteria; –1.9% 
versus 7.8% (adjusted difference: –18.2%,95% CI –30.9 
to –5.6, p=0.005) for change ≥1 grade in ≥1 SIJ; and 
–0.6% versus 6.7% (adjusted difference: –16.4%,95% 
CI –27.9 to –5.0, p=0.005) for change ≥1 grade in 
≥1 SIJ, with shift from 0 to 1 or 1 to 0 considered no 
change.
Conclusion despite the slow radiographic SIJ 
progression rate over 2 years in axSpA, this study 
suggests a lower rate of progression in the SIJ with 





The most frequently observed symptoms in spon-
dyloarthritis (SpA) are axial.1 2 The various criteria 
for SpA (eg, Amor, European Spondyloarthrop-
athy Study Group and, more recently, the Assess-
ment of SpondyloArthritis international Society 
(ASAS) criteria) enable classification of patients 
in the absence of radiographic structural damage, 
that is, non-radiographic axial SpA (nr-axSpA).3–7 
In patients with an inadequate response to non-ste-
roidal anti-inflammatory drugs (NSAIDs) with 
radiographic (r-) or nr-axSpA, anti-tumour necrosis 
factor (TNF) agents have demonstrated a beneficial 
effect on symptoms,8–11 but their structural effect is 
still unclear.12–17 
Structural evaluation of axSpA can be performed 
using conventional radiographs or MRI at the 
spine or pelvic level. Radiographic axSpA studies 
have focused on the spine using a radiography 
scoring system, and data suggest that a structural 
effect either does not exist18 19 or requires studies 
>2 years to be observed.20 21 Questions exist about 
the risk of future structural damage, particularly 
at the sacroiliac joint (SIJ) level, in patients with 
nr-axSpA. Approximately 10% of patients with 
nr-axSpA develop SIJ radiographic damage within 
2 years and 60% within 10 years.22–24
The conventional method for assessing SIJ 
structural damage on radiography is the modified 
New York (mNY) grading system, consisting of a 
semiquantitative scale from 0 (normal) to 4 (total 
ankylosis).2 However, this method has been criti-
cised because of its poor reliability.25 Moreover, this 
grading system has no accepted method to evaluate 
change in radiographic damage except the cate-
gorisation of a patient as having either nr-axSpA or 
r-axSpA: r-axSpA is considered to be at least grade 
2 bilaterally or at least grade 3 unilaterally. Alter-
native outcome measures appear to be more sensi-
tive, such as change in the total score over time, and 
percentage of patients with a change of at least one 
grade in at least one SIJ.24 26
Ideally, a long-term controlled clinical trial would 
address the structural impact of long-term treat-
ment. Additionally, a robust study should include 
both a treatment and a control group. However, it is 
not possible to conduct a study of sufficient length, 
that is, at least 2 years, with a placebo control.21
Another option is to compare a treatment 
cohort from one study to a control cohort in 
another study. This technique has been used to 
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evaluate the structural changes observed at the spine level in 
r-axSpA in patients receiving an anti-TNF. These patients have 
been compared with a control group consisting of patients in 
a study evaluating the natural history of r-axSpA, the OASIS 
cohort.13 16 17 27
All of these considerations prompted us to conduct a study in 
patients with early axSpA aimed at evaluating the radiographic 
changes in the SIJ observed after 2 years of etanercept therapy 
in patients enrolled in a clinical trial (EMBARK) compared 
with usual care in patients enrolled in an observational cohort 
(DESIR).
PAtIents And MetHOds
Details of the EMBARK trial have been described previously.8 28 29 
All patients fulfilled the ASAS criteria for axSpA, but based on a 
central reading procedure, none of them met the mNY criteria 
for radiographic status. Patients were aged ≥18 and <50 years 
with symptoms for >3 months but <5 years, had a Bath Anky-
losing Spondylitis Disease Activity Index (BASDAI) score ≥4 of 
10, and had symptoms of back pain with an inadequate response 
to ≥2 NSAIDs. After a 12-week, double-blind, placebo-con-
trolled period, all patients received etanercept 50 mg once 
weekly during a 92-week open-label period.
The DESIR cohort has been described in detail.23 The study 
included patients aged >18 and <50 years with inflammatory 
back pain for >3 months but <3 years, suggestive of axSpA 
according to the treating rheumatologist. Patients with a history 
of treatment with any biological therapy were excluded.
The present analysis included the patients from the EMBARK 
trial with available baseline and 2-year pelvic radiographs, and 
patients from the DESIR cohort who met the ASAS criteria for 
axSpA, did not receive any biological therapy during the first 
two years of follow-up and had baseline and 2-year pelvic 
radiographs.
Grading of radiographic sacroiliitis
Radiographic sacroiliitis was graded using the 0–4 grade scale 
for the left and right SIJ from the mNY grading system.2 The 
scale is provided below:
 ► Grade 0: normal.
 ► Grade 1: suspicious changes.
 ► Grade 2: minimal abnormality—small localised areas with 
erosion or sclerosis, without alteration in the joint width.
 ► Grade 3: unequivocal abnormality—moderate or advanced 
sacroiliitis with one or more of erosions, evidence of scle-
rosis, widening, narrowing or partial ankylosis.
 ► Grade 4: severe abnormality—total ankylosis.
reading the radiographs
The SIJ radiographs from the DESIR and EMBARK cohorts were 
anonymised so that the readers were unaware of the chronology 
of the films and the original patient cohort. The three trained and 
experienced readers, who were not readers used for screening in 
either DESIR or EMBARK, met via videoconference for a cali-
bration session prior to the start of this analysis. They graded 
each joint at each time point, with a scale from 0 to 4 per the 
mNY grading system.
Assessments
The primary endpoint was change in total SIJ score at week 
104. Total SIJ score was obtained by adding the scores of both 
SIJs according to the mNY grading system (0–4 per SIJ, range 
from 0 to 8); thus the change could range from –8 to +8. For 
this endpoint, the mean change of the three readers’ values was 
used. Three binary endpoints were also evaluated: (1) propor-
tion of patients switching from mNY criteria negative at base-
line to mNY criteria positive at week 104 and the proportion 
of patients switching from mNY criteria positive at baseline to 
mNY criteria negative at week 104 (based on the central reading 
for the current analysis); and (2) proportion of patients with 
change (improvement or worsening in SIJ score of ≥1) in at least 
one SIJ. The third binary endpoint excluded minimal or doubtful 
changes (changes from normal appearance (grade 0) to ‘suspi-
cious’ abnormalities of the SIJ (grade 1)) from the improved 
or worsened categories: proportion of patients with change 
(improvement or worsening in SIJ score of ≥1) in at least one 
SIJ, with a shift from 0 to 1 (in the worsened joint) or from 1 to 
0 (in the improved joint) considered no change. For these binary 
endpoints, improvement or worsening was assigned only if at 
least two of the three readers agreed on the direction of change.
Other collected data
In both studies, patient demographics and clinical outcome 
measures of disease activity were collected at baseline and 
throughout the duration of the follow-up. The baseline SIJ 
MRI evaluating the presence of inflammation according to the 
Spondyloarthritis Research Consortium of Canada (SPARCC) 
method30 was assessed separately in EMBARK and DESIR using 
a central reading procedure previously described.29 31 A score ≥2 
was considered an indicator of SIJ inflammation on MRI.32
statistical analysis
This analysis included the completer population, defined as 
having pelvic radiographs available at baseline and 2 years. 
Baseline characteristics were analysed using either the Wilcoxon 
rank-sum or the Mantel-Haenszel χ2 test. The radiographic 
analyses were conducted without covariates (unadjusted anal-
ysis) and also with the following covariates as potential base-
line confounders (adjusted analysis): sex, symptom duration, 
smoking status, human leucocyte antigen (HLA)-B27 status, 
Ankylosing Spondylitis Disease Activity Score (ASDAS) with 
C reactive protein, SPARCC MRI SIJ score and total SIJ score 
based on the mNY grading system. One-way analysis of variance 
was used to compare study cohorts for the unadjusted difference, 
and analysis of covariance was used for the adjusted difference.
The a priori primary outcome measure was the absolute change 
in total SIJ score adjusted for baseline covariates. For each of the 
three binary endpoints, the percentage of patients with disease 
progression (worsening) and the percentage of patients with 
disease regression (improvement) was determined per group. 
Additionally, the net percentage of patients with progression 
was defined as the number of patients with worsening minus the 
number of patients with improvement, divided by the total study 
population. The between-group difference in the net percentage 
of patients with progression was reported for each of the three 
binary endpoints. A cumulative probability plot was generated 
to compare the change in SIJ radiography score from baseline 
to week 104 for the control and etanercept cohorts. Change was 
defined as the average change of the three readers.
results
The EMBARK trial included 225 randomised patients; a 
complete data set was available for 162 patients. The DESIR 
cohort study enrolled 708 patients; 506 of these patients did not 
receive a biological therapy during the 2 years of follow-up, 283 
of these 506 patients fulfilled the ASAS criteria for axSpA and 
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193 had both baseline and 2-year pelvic radiographs available 
and qualified for this study. Demographics and baseline disease 
characteristics are provided in table 1.
At baseline, several differences existed between the groups: 
a higher proportion of males and longer disease duration in 
the etanercept group, and a higher proportion of smokers 
and HLA-B27-positive patients in the control group. Because 
all EMBARK patients were eligible for initiation of anti-TNF 
therapy and none of the DESIR cohort received an anti-TNF 
during the 2-year follow-up period, it is not surprising that the 
disease activity markers of BASDAI, ASDAS and SPARCC MRI 
SIJ inflammation were significantly higher in the etanercept 
group at baseline. Conversely, total SIJ score was slightly but 
significantly higher in the control group.
After 104 weeks, there was a slightly positive change (wors-
ening) in the total SIJ score for the control group versus a 
slightly negative change (improvement) in the etanercept group 
in the adjusted analysis (least-squares mean change: 0.08 (95% 
CI −0.04 to 0.20) vs −0.14 (95% CI −0.26 to −0.01)). The 
adjusted between-group difference in change (etanercept − 
control) was significant: −0.22 (95% CI −0.38 to −0.06, 
p=0.008); the unadjusted between-group difference was not 
significant: −0.11 (95% CI −0.25 to 0.02, p=0.10).
Figure 1 presents the cumulative probability plot for the 
change in SIJ radiography score over 104 weeks. The control 
cohort trended towards worsening, with more patients having a 
positive score. In contrast, the etanercept cohort trended towards 
improvement, with more patients having a negative score.
The observed radiographic changes from baseline to week 
104 are shown in table 2. For change in mNY criteria, the net 
percentage of patients with progression was lower in the etaner-
cept versus the control group; however, the difference between 
the groups was not statistically significant: −1.9% versus 1.6% 
(adjusted difference for etanercept minus control: −4.7%, 95% 
CI –9.9 to 0.5, p=0.07). For the other two binary endpoints, 
the net percentage of patients with progression was significantly 
lower in the etanercept versus the control group: −1.9% versus 
7.8% (adjusted difference: −18.2%, 95% CI −30.9 to −5.6, 
p=0.005) for change ≥1 grade in at least one SIJ; and −0.6% 
versus 6.7% (adjusted difference: −16.4%, 95% CI −27.9 to 
−5.0, p=0.005) for change ≥1 grade in at least one SIJ, with 
shift from 0 to 1 or 1 to 0 considered no change.
Figure 2 presents the net percentage of patients with progres-
sion in the two study groups for the three binary endpoints.
dIsCussIOn
This study supports the existence of a small structural effect 
of anti-TNF therapy in the SIJ using plain pelvic radiographs 
as the primary assessment tool and the mNY grading system as 
the outcome measure. It also confirms the relatively slow rate 
of radiographic progression in the SIJ in terms of shifting from 
non-radiographic to radiographic status according to the mNY 
criteria over a 2-year period.
An assessment of 2-year SIJ radiographic progression in early 
axSpA was also conducted in the German Spondyloarthritis 
Inception Cohort (GESPIC), a cohort comparable to DESIR.24 A 
similar rate of SIJ radiographic progression was observed, with a 
mean change in the SIJ score of 0.07 (95% CI –0.05 to 0.19) and 
0.09 (95% CI –0.03 to 0.21) for the left and right SIJ, respec-
tively.24 Moreover, in the GESPIC cohort, after 2 years, 11 of the 
95 patients with nr-axSpA at baseline met the mNY criteria for 
r-axSpA (ie, worsened).24 Additionally, 3 of the 115 patients with 
r-axSpA at baseline did not fulfil the mNY criteria at year 2 (ie, 
improved).24 Calculating the net rate of progression for the full 
study population results in a rate of 3.8% ((11 – 3)/(95+115)). 
This is similar to the data observed in the present study for the 
DESIR patients (control group), with a net progression rate of 
1.6% (95% CI −1.3% to 4.4%). The slight difference between 
the two studies may be due to chance or may be explained by 
different patient phenotypes, in particular, the proportion of 
patients with SIJ inflammation on MRI (greater in the GESPIC 
cohort than in this DESIR subgroup).
When considering an outcome parameter based on a semiquan-
titative variable (score 0–4 per side), including different types of 
damage, collected in the left and right joints, some concerns may 






Age, years 32.2 (7.0) 31.8 (7.7) 0.47*
Male, n/N (%) 100/193 (51.8) 106/162 (65.4) 0.01†
Symptom duration, years 1.7 (1.0) 2.4 (1.8) <0.001*
Current smoker, n/N (%) 70/192 (36.5) 37/162 (22.8) 0.006†
HLA-B27(+), n/N (%) 162/193 (83.9) 113/156 (72.4) 0.009†
BASDAI (0–10) 3.6 (1.9) 5.9 (1.8) <0.001*
ASDAS 2.2 (0.9) 3.0 (1.0) <0.001*
BASFI (0–10 cm VAS) 2.2 (2.0) 4.0 (2.4) <0.001*
CRP, mg/L 5.4 (7.5) 6.9 (11.2) 0.06*
SPARCC MRI SIJ score (0–72) 5.8 (9.5) 8.4 (11.0) <0.001*
SPARCC MRI SIJ score ≥2, 
n/N (%)
78/191 (40.8) 95/159 (59.7) <0.001†
Total SIJ score (mNY grade 
0–8)
1.9 (1.6) 1.5 (1.2) 0.03*
SIJ score met mNY 
criteria, n/N (%)
39/193 (20.2) 19/162 (11.7) 0.03†
Values are mean (SD) unless otherwise noted.
*Wilcoxon rank-sum.
†Mantel-Haenszel.
ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing 
Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional 
Index; CRP, C-reactive protein; HLA, human leucocyte antigen; mNY, modified 
New York; SIJ, sacroiliac joint; SPARCC, Spondyloarthritis Research Consortium of 
Canada; VAS, visual analogue scale.
Figure 1 Cumulative probability of change in sacroiliac joint (SIJ) 
radiography score from baseline to week 104 for the control and 
etanercept cohorts, average of the readers.
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be raised. Semiquantitative scores may not be translated into 
continuous scores without consideration since it is unknown if 
the steps in the semiquantitative score are equidistant. While this 
is a technical limitation of our study, this approach is frequently 
used in medicine in general and in rheumatology in particular, 
and we do not believe that it has influenced the results.
Dichotomisation is a frequently used technique to overcome 
scaling issues related to semiquantitative scores and interpreta-
tional concerns from continuous scores. Dichotomisation also 
assists in the analysis of non-normally distributed data. It is 
tempting for clinicians to interpret radiographic change scores as 
dichotomies (those that progress vs those that do not; those that 
have nr-axSpA vs those that have r-axSpA). However, dichoto-
misation is a simplification of the truth because it largely ignores 
measurement error. Measuring radiographic change in patients 
with SpA is a challenge since the true change (‘the signal’) in a 
patient is usually outweighed by spurious change (‘the noise’) 
due to differences in technique and inherent rater variability. An 
observed difference between groups is only credible if the scores 
have been obtained under unbiased conditions and all possible 
directions of change have been considered.
‘Net percentage of patients with progression’ is a concept 
we explored to combine the advantages of dichotomisation 
(‘progressor’ or ‘non-progressor’) while preserving the option 
of adjusting for measurement error. It is an artificial concept 
in terms of interpretation since it appears possible in a single 
patient to adjust the true signal for the noise of measurement 
error, which is not the case. Net percentage of patients with 
progression should be interpreted at the group level. Although 
more patients had disease progression than disease regression 
overall, this difference cannot be translated to an individual 
patient. Therefore, the concept does not elementarily differ 
from the comparison of group means.
Another potential issue when using the mNY grading system 
as an outcome measure is that two concepts are mixed: repair 
(sclerosis) and destruction (joint erosion). One patient may have 
a change in sclerosis and another may have a change in erosion, 
and the grade change could be the same. Additionally, the results 
can vary between readers since the inter-reader reliability of this 
approach is known to be quite poor.25 26 In EMBARK there was 
a greater proportion of patients with regression than progres-
sion, resulting in a negative parameter estimate for progression 
rate. This may be due to measurement error or a true repair 
process with a reduction in erosions.
The switch from a continuous or semiquantitative to a binary 
variable (progression yes/no) necessitates choosing a cut-off. 
Because the conventional yet arbitrary mNY criteria distin-
guish between radiographic and non-radiographic status, it was 
tempting to use these to describe a patient at a particular time 
point and to estimate the natural disease history. It was also 
tempting to present the results in a simpler, more understand-
able manner, such as change of ≥1 grade in ≥1 SIJ. We used 
the approach proposed by the GESPIC investigators. However, 
because of the difficulty in distinguishing a grade 0 from a grade 
1, we modified this system by excluding the change from grade 
0 to grade 1 for the worsened joint or from grade 1 to 0 for the 
improved joint.26
These results suggest a significant structural effect of etanercept 
in the SIJ. The treatment group was not compared with a control 
group within a prospective randomised controlled trial; rather, 
it was compared with a contemporary cohort of patients. Conse-
quently, the baseline characteristics differed between the two 
groups, particularly the disease activity. All patients in EMBARK 
were eligible for anti-TNF therapy; the DESIR patients in this 
study did not receive biological therapy. Therefore, we adjusted 
for covariates that may affect radiographic progression.24 26 33
To our knowledge, this is the first study to evaluate the 
anti-TNF structural effect in the SIJ using plain pelvic radiog-
raphy as the assessment tool and the mNY grading system as 
the scoring method. These results should be considered within 
the context of the literature. Previous studies of radiographic 
progression in axSpA evaluated the spine since structural damage 
in the spine correlates with functional impairment. However, 
study results suggest that a longer period of evaluation is needed 
to observe a structural anti-TNF effect in the spine.13 16 17 34 35 
The clinical relevance of our study may be more difficult to 
interpret since the correlation between a change in radiographic 
SIJ damage and the functional capacity of a patient is usually 
considered poor. Future studies are needed to better evaluate the 
predictive validity of this outcome measure.
table 2 Observed radiographic changes from baseline to week 104
between-group differences in net % patients 
with progression,
etanercept—Control (95% CI)
endpoint Cohort Improved n/n (%) Worsened n/n (%)
net % patients 
with progression,*† 
unadjusted
(95% CI) unadjusted analysis Adjusted analysis‡






1.6% (−1.3 to 4.4)
−1.9% (−4.9 to 1.2)
−3.4% (−7.6 to 0.8)
p=0.11
−4.7% (−9.9 to 0.5)
p=0.07






7.8% (0.6 to 15.0)







∆ ≥1 grade in ≥1 SIJ; 








6.7% (0.3 to 13.2)







Based on two of three readers assigning same category; otherwise considered no change.
Some patients started with lowest possible score and could not improve.
*Net % patients with progression=number of patients with worsening minus the number of patients with improvement, divided by the study population.
†One-way analysis of variance.
‡Adjusted for these covariates at baseline: sex, symptom duration, smoking status, human leucocyte antigen-B27 status, Ankylosing Spondylitis Disease Activity Score, 
Spondyloarthritis Research Consortium of Canada MRI SIJ score and SIJ mNY grade.
∆, change; mNY, modified New York; SIJ, sacroiliac joint.
 on 6 A









is: first published as 10.1136/annrheum






225Dougados M, et al. Ann Rheum Dis 2018;77:221–227. doi:10.1136/annrheumdis-2017-212008
Clinical and epidemiological research
Figure 2 Net percent of patients with progression (number of patients with worsening minus the number of patients with improvement, divided by 
the study population) from baseline to week 104 in each study group for the three binary endpoints: (A) change in modified New York (mNY) criteria, 
adjusted analysis and (B) unadjusted analysis; (C) change of ≥1 grade in ≥1 sacroiliac joint (SIJ), adjusted analysis and (D) unadjusted analysis; and 
(E) change of ≥1 grade in ≥1 SIJ with shift from 0 to 1 and from 1 to 0 considered no change, adjusted analysis and (F) unadjusted analysis.
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Our study has several strengths. First, both study cohorts had a 
large sample size. Second, the scoring methodology was designed 
to avoid and adjust for bias, that is, the three independent, trained 
readers were unaware of the chronology of the radiographs and 
the patient cohort. Third, the study included a control group. Even 
though both cohorts were not randomised as a whole, the control 
group was an appropriate comparison for the etanercept group.
These results further support a structural anti-TNF effect in the 
SIJ.36 The data are promising, but additional studies are needed 
to confirm the validity of these outcome measures and to evaluate 
the structural effect of various therapies in the SIJ using advanced 
imaging techniques.
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